TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04325698
Drug: PF-06439535 (CN)
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
Study: NCT00005993
Drug: recombinant human stem cell factor
Normalized name: antihemophilic factor, human recombinant
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04325698
Drug: Bevacizumab-EU
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
Study: NCT04325698
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Study: NCT04325698
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Study: NCT03813147
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03813147
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally and IV
Study: NCT03813147
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03813147
Drug: Pevonedistat
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04206176
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 45mg twice daily per oral administration
Study: NCT00962091
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib OS Alisertib PIC Alisertib PIC
Study: NCT02631460
Drug: pemetrexed 500 mg/m2
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: d1, every 3 weeks
Study: NCT02631460
Drug: carboplatin AUC=5
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1, every 3 weeks
Study: NCT03104426
Drug: Darbepoetin Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
Study: NCT00504491
Drug: Rituximab-CHOP-Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Four Rituximab - CHOP courses will be given The courses will be given every 21 days
Study: NCT02261662
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone
Study: NCT02261662
Drug: Betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Steroids alone will be used; Betamethasone
Study: NCT00718380
Drug: ABT-869
Normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
Study: NCT00518635
Drug: Nutropin
Normalized name: Nutropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutropin 0.1 mg/day self-administered once a day
Study: NCT01328548
Drug: Zostavax
Normalized name: Zostavax
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03491631
Drug: SHR9146+SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W
Study: NCT03491631
Drug: SHR9146+SHR-1210+Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
Study: NCT00351637
Drug: Sublingual Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03326960
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
Study: NCT03326960
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
Study: NCT03326960
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
Study: NCT03221842
Drug: C1-esterase inhibitor
Normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
Study: NCT04659382
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab combined to standard chemotherapy (XELOX + bevacizumab) and targeted therapy in patients whose tumour has been made immunogenic by radiotherapy (Therasphere) and ICI (atezolizumab).
Study: NCT04659382
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard targeted therapy associated with XELOX for first line treament of metastatic CRC (in pMMR and/or MSS patients)
Study: NCT00900731
Drug: Indacaterol 150 μg
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT00900731
Drug: Tiotropium 18 μg
Normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
Study: NCT00900731
Drug: Placebo to indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT00900731
Drug: Placebo to tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
Study: NCT02173990
Drug: Aflibercept-FOLFIRI
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~* Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin\* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~* 5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~  * \*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²
Study: NCT01184105
Drug: Intervention A
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
Study: NCT00247507
Drug: acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00462254
Drug: ROZEREM
Normalized name: Rozerem
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
Study: NCT04106050
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02953106
Drug: Azelastine-Fluticasone Nasal
Normalized name: azelastine-fluticasone nasal
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
Study: NCT00462254
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
Study: NCT02145325
Drug: Expanded Tregs
Normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03996408
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a multi-target receptor tyrosine kinase inhibitor
Study: NCT01615211
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
Study: NCT01615211
Drug: Trilostane
Normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
Study: NCT00409695
Drug: Low Dose Thymoglobulin (ATG)
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
Study: NCT00409695
Drug: High Dose Thymoglobulin (ATG)
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
Study: NCT03195647
Drug: Potassium
Normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.
Study: NCT00855205
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
Study: NCT01306045
Drug: MK-2206
Normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week
Study: NCT01306045
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)
Study: NCT01306045
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)
Study: NCT01306045
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28
Study: NCT04608344
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as single dose tablet orally.
Study: NCT04608344
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Administered as tablet orally once daily for 11 days.
Study: NCT03191864
Drug: APT-1011
Normalized name: tetracycline
DrugBank: APT-101 (DB18003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
Study: NCT00534079
Drug: Dornase alfa (Pulmozyme)
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 2,5 ml per day, inhalation use, for 28 days
Study: NCT03144843
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
Study: NCT01794273
Drug: ephedrine and phenylephrine
Normalized name: Carbetapentane and chlorpheniramine and ephedrine and phenylephrine only product
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01794793
Drug: Pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
Study: NCT01794793
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
Study: NCT01794793
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
Study: NCT03647774
Drug: Extended release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 380mg injectable extended release naltrexone every four weeks
Study: NCT02044874
Drug: APD356-lorcaserin hydrochloride
Normalized name: Lorcaserin Hydrochloride
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01563367
Drug: Iron isomaltoside 1000 (Monofer®)
Normalized name: ferric carboxymaltose
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
Study: NCT04494763
Drug: Propanolol
Normalized name: Propanolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-selective Beta-blocker
Study: NCT00082017
Drug: UCN-01 (7-hydroxystaurosporine)
Normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 21 days.
Study: NCT04005144
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04005144
Drug: Brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01848743
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00084214
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00146614
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00146614
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01848743
Drug: lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00778102
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus 400mg/m2, day 1 every 2 weeks
Study: NCT00778102
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
Study: NCT00778102
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
Study: NCT00778102
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 165mg/m2 1-hour iv infusion, day 1 every 2 weeks
Study: NCT00778102
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study: NCT00778102
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/kg iv day 1 every 2 weeks
Study: NCT03204487
Drug: Tafluprost 15µg/ml
DrugBank: Tafluprost (DB08819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp \& Dohme, Wien)
Study: NCT00779532
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules containing 400 mg moxifloxacin, on Day 14 only
Study: NCT00779532
Drug: NOMAC-E2 (Org 10486-0 + Org 2317)
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
Study: NCT00779532
Drug: Moxifloxacin placebo
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
Study: NCT03031574
Drug: SUVN-D4010
Normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT02868567
Drug: dalfampridine
Normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill open label
Study: NCT00787917
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab subcutaneous injections of 600 mg daily.
Study: NCT00787917
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole twice daily with a maximum daily dose of 400 mg.
Study: NCT01959698
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01959698
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01959698
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01959698
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03263689
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
Study: NCT03800836
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28 day cycle for all arms except for arms F1/F2 where it will be administered at a dose of 300 milligrams (mg) orally daily for the first two cycles and 400 mg for the remaining three cycles.
Study: NCT03800836
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion on Days 1, 8, and 15 of each 28 day cycle for all arms, with the exceptions of Arms F1, F2, G1 and G2, where it will be also administered on Day 22 as well, of each 28 day cycle.
Study: NCT03800836
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28 day cycle for all arms, although in Arms C1/C2, it will be administered on Day 15 of Cycle 1 followed by Days 1 and 15 in subsequent cycles.
Study: NCT03800836
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administered by IV infusion at a dose of 100 mg/m\^2 on Days 1, 8, and 15 of each 28 day cycle.
Study: NCT02016729
Drug: AMG 232
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given an an oral tablet in escalating doses.
Study: NCT03800836
Drug: AC
Normalized name: Ac
DrugBank: Actinium (DB12860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (Doxorubicin and Cyclophosphamide) will be administered by IV infusion at 60 mg/m\^2 and 600 mg/m\^2 respectively on Days 1 and 15 of Cycles 1 and 2 for Arms F1, F2, G1 and G2.
Study: NCT03817957
Drug: Polyglucoferron
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT03817957
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous administration
Study: NCT03817957
Drug: Ferrous Sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT00784550
Drug: Tiotropium Bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-acting muscarinic antagonist